Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. XFOR
stocks logo

XFOR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
1.90M
+237.48%
-4.290
+102.61%
2.27M
+305.71%
-2.990
-44.63%
--
--
-2.643
-55.94%
Estimates Revision
The market is revising No Change the revenue expectations for X4 Pharmaceuticals, Inc. (XFOR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 8.57%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+8.57%
In Past 3 Month
Wall Street analysts forecast XFOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XFOR is 57.75 USD with a low forecast of 7.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast XFOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XFOR is 57.75 USD with a low forecast of 7.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.800
sliders
Low
7.00
Averages
57.75
High
120.00
Current: 3.800
sliders
Low
7.00
Averages
57.75
High
120.00
H.C. Wainwright
NULL -> Buy
maintain
$5
2025-11-10
Reason
H.C. Wainwright
Price Target
$5
2025-11-10
maintain
NULL -> Buy
Reason
H.C. Wainwright raised the firm's price target on X4 Pharmaceuticals to $5 from $3.50 and keeps a Buy rating on the shares post the Q3 report. The company executed a corporate restructuring to ensure long-term growth, the analyst tells investors in a research note.
Stifel
Buy
to
Buy
downgrade
$9
2025-11-05
Reason
Stifel
Price Target
$9
2025-11-05
downgrade
Buy
to
Buy
Reason
Stifel lowered the firm's price target on X4 Pharmaceuticals to $7.50 from $9 and keeps a Buy rating on the shares. The firm updated the company's model post the earnings report and corporate update. The reduced target reflects revised financing assumptions, including the impact of X4's October financing, the analyst tells investors in a research note.
Stifel
Stephen Willey
Buy
downgrade
$30 -> $9
2025-08-29
Reason
Stifel
Stephen Willey
Price Target
$30 -> $9
2025-08-29
downgrade
Buy
Reason
Stifel analyst Stephen Willey lowered the firm's price target on X4 Pharmaceuticals to $9 from $30 and keeps a Buy rating on the shares following "a number of significant changes" over the past couple of weeks, most notably the "complete overhaul" of the senior leadership team and another recapitalization with the $85M PIPE deal. These changes increase the likelihood mavorixafor is "afforded the opportunity to fulfill its potential" in chronic neutropenia, which the firm believes to be "a multi-billiondollar addressable market opportunity of significant unmet medical need," the analyst tells investors.
H.C. Wainwright
Swayampakula Ramakanth
Buy
downgrade
$7
2025-08-13
Reason
H.C. Wainwright
Swayampakula Ramakanth
Price Target
$7
2025-08-13
downgrade
Buy
Reason
H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm's price target on X4 Pharmaceuticals to $3.50 from $7 and keeps a Buy rating on the shares. The firm updated the company's model to reflect the Q2 report and private placement expected to close on August 13. The capital raised strengthens the balance sheet and aids in meeting the Hercules Loan covenant obligations, the analyst tells investors in a research note.
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$1.5
2025-03-27
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$1.5
2025-03-27
Reiterates
Strong Buy
Reason
Cantor Fitzgerald
Kristen Kluska
Buy
Reiterates
$3
2025-03-26
Reason
Cantor Fitzgerald
Kristen Kluska
Price Target
$3
2025-03-26
Reiterates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for X4 Pharmaceuticals Inc (XFOR.O) is -0.34, compared to its 5-year average forward P/E of -1.99. For a more detailed relative valuation and DCF analysis to assess X4 Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.99
Current PE
-0.34
Overvalued PE
-0.48
Undervalued PE
-3.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
120.49
Current PS
2.33
Overvalued PS
369.73
Undervalued PS
-128.75
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 9661.69% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 9661.69% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

XFOR News & Events

Events Timeline

(ET)
2025-11-05
07:04:20
X4 Pharmaceuticals announces Q3 earnings per share of 69 cents, below consensus estimate of 84 cents.
select
2025-10-24 (ET)
2025-10-24
06:35:24
X4 Pharmaceuticals Prices 45.87M Share Spot Secondary Offering at $2.85
select
2025-10-23 (ET)
2025-10-23
16:03:05
X4 Pharmaceuticals Reveals Common Stock Offering, Amount Not Disclosed
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
11-24Yahoo Finance
Examining X4 Pharmaceuticals' Story Following Leadership Transitions and Recent Funding

  • Analyst Price Target Adjustments: X4 Pharmaceuticals' consensus analyst price target has decreased from $8.70 to $7.38 due to updated financing scenarios and changes in leadership, reflecting a more cautious outlook on expected returns.

  • Bullish and Bearish Perspectives: While Stifel maintains a Buy rating despite lowering its price target, indicating confidence in the company's long-term prospects, there are concerns about valuation and the impact of recent recapitalizations on shareholders.

  • Capital Raise and Strategic Restructuring: The company raised $135 million through a follow-on equity offering and announced a workforce reduction of about 50% to focus on key development initiatives, aiming for significant cost savings.

  • Financial Metrics Overview: Key financial metrics have been adjusted, with revenue growth expectations lowered and net profit margins increased, suggesting improved profitability despite slower sales expansion.

[object Object]
Preview
5.0
10-29NASDAQ.COM
Insider Buying Update for Tuesday, October 28: CRMD and XFOR

  • CorMedix Insider Purchase: Myron Kaplan, Director of CorMedix, purchased 25,000 shares at $11.02 each for a total of $275,500, marking his first buy in the past year, and is currently up 7.4% based on today's trading high.

  • X4 Pharmaceuticals Insider Purchase: Adam R. Craig, Executive Chairman of X4 Pharmaceuticals, bought 86,206 shares at $2.90 each for a total of $249,997, and is up 36.6% based on today's trading high.

  • Market Performance: CorMedix shares are up about 2.5% on Tuesday, while X4 Pharmaceuticals shares have increased by approximately 0.7%.

  • Disclaimer: The views expressed in the report are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.

[object Object]
Preview
9.5
10-28NASDAQ.COM
Healthcare Rally: Pulmonx, UHS, and X4 Experience After-Hours Gains Following Strategic Announcements

  • Pulmonx Corp. Performance: Pulmonx Corp. saw a significant increase of 33.33% to $2.08 after announcing preliminary Q3 2025 revenue of approximately $21.5 million and leadership changes, including the reappointment of Glen French as President and CEO.

  • Q32 Bio Inc. Gains: Q32 Bio Inc. experienced a 12.5% rise to $3.15 in after-hours trading, although no specific news was reported to explain this increase.

  • Universal Health Services Update: Universal Health Services Inc. climbed 7.41% to $229.90 following its Q3 results and a revised full-year forecast, along with a $1.5 billion increase in its stock repurchase program.

  • X4 Pharmaceuticals Offering: X4 Pharmaceuticals Inc. gained 5.35% to $3.94 after completing a public offering of 52.8 million shares, raising approximately $155.3 million before expenses, increasing total shares outstanding to 79.2 million.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is X4 Pharmaceuticals Inc (XFOR) stock price today?

The current price of XFOR is 3.8 USD — it has increased 16.92 % in the last trading day.

arrow icon

What is X4 Pharmaceuticals Inc (XFOR)'s business?

X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.

arrow icon

What is the price predicton of XFOR Stock?

Wall Street analysts forecast XFOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XFOR is 57.75 USD with a low forecast of 7.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is X4 Pharmaceuticals Inc (XFOR)'s revenue for the last quarter?

X4 Pharmaceuticals Inc revenue for the last quarter amounts to 28.81M USD, decreased % YoY.

arrow icon

What is X4 Pharmaceuticals Inc (XFOR)'s earnings per share (EPS) for the last quarter?

X4 Pharmaceuticals Inc. EPS for the last quarter amounts to 1.20 USD, decreased -115.44 % YoY.

arrow icon

What changes have occurred in the market's expectations for X4 Pharmaceuticals Inc (XFOR)'s fundamentals?

The market is revising No Change the revenue expectations for X4 Pharmaceuticals, Inc. (XFOR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 8.57%.
arrow icon

How many employees does X4 Pharmaceuticals Inc (XFOR). have?

X4 Pharmaceuticals Inc (XFOR) has 143 emplpoyees as of December 05 2025.

arrow icon

What is X4 Pharmaceuticals Inc (XFOR) market cap?

Today XFOR has the market capitalization of 112.54M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free